# Octagon Capital Advisors LP: Form 13F holdings

An institutional investment manager in NEW YORK, NY. SEC CIK 1839435.

- Quarter ended: 2026-06-30
- Filed: 2026-08-14
- Reported value: $1.11bn
- Positions: 27 (27 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1839435/000183943526000004/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [DIANTHUS THERAPEUTICS INC (DNTH)](/companies/dnth.md) | COM | $179.5m | 16.1% | 1,841,667 |  | Reduced −105,000 |
| [DEFINIUM THERAPEUTICS INC (DFTX)](/companies/dftx.md) | COM SHS | $138.8m | 12.5% | 2,950,000 |  | Added +510,000 |
| [ABIVAX SA (ABVX)](/companies/abvx.md) | SPONSORED ADS | $132.3m | 11.9% | 993,000 |  | Added +316,000 |
| [COGENT BIOSCIENCES INC (COGT)](/companies/cogt.md) | COM | $90.9m | 8.2% | 2,350,000 |  | Unchanged |
| [ALUMIS INC (ALMS)](/companies/alms.md) | COM | $79.7m | 7.2% | 2,830,700 |  | Unchanged |
| [ARRIVENT BIOPHARMA INC (AVBP)](/companies/avbp.md) | COM | $68.5m | 6.2% | 1,971,054 |  | Unchanged |
| [TAYSHA GENE THERAPIES INC (TSHA)](/companies/tsha.md) | COM SHS | $66.0m | 5.9% | 9,693,244 |  | Added +833,333 |
| [BIOAGE LABS INC (BIOA)](/companies/bioa.md) | COM | $42.8m | 3.9% | 1,748,000 |  | Unchanged |
| [MIRUM PHARMACEUTICALS INC (MIRM)](/companies/mirm.md) | COM | $39.7m | 3.6% | 338,900 |  | Unchanged |
| [KYMERA THERAPEUTICS INC (KYMR)](/companies/kymr.md) | COM | $35.5m | 3.2% | 310,000 |  | Reduced −115,000 |
| [AKTIS ONCOLOGY INC (AKTS)](/companies/akts.md) | COM | $31.0m | 2.8% | 960,847 |  | Unchanged |
| [XENON PHARMACEUTICALS INC (XENE)](/companies/xene.md) | COM | $29.6m | 2.7% | 490,000 |  | Unchanged |
| ERASCA INC | CALL | $23.0m | 2.1% | 1,255,000 | Call | New +1,255,000 |
| [PALISADE BIO INC (PALI)](/companies/pali.md) | COM | $21.5m | 1.9% | 10,276,317 |  | Unchanged |
| [OCULAR THERAPEUTIX INC (OCUL)](/companies/ocul.md) | COM | $20.4m | 1.8% | 2,075,000 |  | Reduced −1,091,600 |
| [DISC MEDICINE INC (IRON)](/companies/iron.md) | COM | $19.7m | 1.8% | 270,000 |  | Unchanged |
| [SUMMIT THERAPEUTICS INC (SMMT)](/companies/smmt.md) | COM | $18.2m | 1.6% | 1,250,000 |  | New +1,250,000 |
| PHARVARIS N V | COM | $15.8m | 1.4% | 456,721 |  | Added +291,721 |
| [ADLAI NORTYE LTD (ANL)](/companies/anl.md) | SPONSORED ADS | $10.7m | 1.0% | 934,716 |  | New +934,716 |
| [PRECISION BIOSCIENCES INC (DTIL)](/companies/dtil.md) | COM NEW | $10.6m | 1.0% | 1,350,000 |  | Reduced −886,732 |
| [DBV TECHNOLOGIES S A (DBVT)](/companies/dbvt.md) | SPONSORED ADS | $9.4m | 0.8% | 574,200 |  | Unchanged |
| [FAETH THERAPEUTICS INC (FTH)](/companies/fth.md) | COM NEW | $9.0m | 0.8% | 361,010 |  | New +361,010 |
| [GYRE THERAPEUTICS INC (GYRE)](/companies/gyre.md) | COM | $6.3m | 0.6% | 954,416 |  | New +954,416 |
| [TREVI THERAPEUTICS INC (TRVI)](/companies/trvi.md) | COM | $5.9m | 0.5% | 315,000 |  | Reduced −1,170,000 |
| [UNICYCIVE THERAPEUTICS INC (UNCY)](/companies/uncy.md) | COM NEW | $4.7m | 0.4% | 1,000,000 |  | Unchanged |
| [CONTEXT THERAPEUTICS INC (CNTX)](/companies/cntx.md) | COM | $1.7m | 0.2% | 3,050,000 |  | Reduced −2,200,000 |
| GOSSAMER BIO INC | COM | $1.3m | 0.1% | 7,750,000 |  | Unchanged |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [BRIDGEBIO ONCOLOGY THERAPEUT (BBOT)](/companies/bbot.md) | COM NEW | $0 | 0.0% | 0 |  | Sold out −719,000 |
| CENTESSA PHARMACEUTICALS PLC | SPONSORED ADS | $0 | 0.0% | 0 |  | Sold out −750,000 |
| [EVOMMUNE INC (EVMN)](/companies/evmn.md) | COM SHS | $0 | 0.0% | 0 |  | Sold out −143,472 |
| KALVISTA PHARMACEUTICALS INC | COM | $0 | 0.0% | 0 |  | Sold out −1,450,000 |
| [LEXEO THERAPEUTICS INC (LXEO)](/companies/lxeo.md) | COM | $0 | 0.0% | 0 |  | Sold out −1,100,000 |
| [PERSPECTIVE THERAPEUTICS INC (CATX)](/companies/catx.md) | COM NEW | $0 | 0.0% | 0 |  | Sold out −791,555 |
| TERNS PHARMACEUTICALS INC | COM | $0 | 0.0% | 0 |  | Sold out −530,000 |

Source: SEC EDGAR, Form 13F-HR, accession 0001839435-26-000004. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.